Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human coagulation factor VIII for injection in treated severe hemophilia A
NCT06297655Phase 3Active, not recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Nov 2024
- Primary completion
- Jul 2026
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human coagulation factor VIII adenovirus in hemophilia A, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Started Nov 2024; status: active, not recruiting.
02
Drugs
recombinant human coagulation factor VIII adenovirus
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT06297655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06297655.